Cardiovascular protection
Reduces LDL oxidation, inhibits platelet aggregation, improves endothelial function, and modestly lowers blood pressure. Partly attributed to the 'French Paradox' of low CVD rates in red wine-consuming populations.
Sirtuin activation and longevity
Activates SIRT1 deacetylase, mimicking caloric restriction signaling. This upregulates mitochondrial biogenesis, improves metabolic efficiency, and activates stress resistance pathways.
Anti-inflammatory effects
Inhibits NF-κB transcription factor, reducing production of inflammatory cytokines (TNF-α, IL-6, IL-1β) and COX enzymes. Clinically shows reduced CRP levels in metabolic syndrome patients.
Blood sugar regulation
Improves insulin sensitivity through SIRT1/AMPK activation and reduces postprandial glucose spikes. RCTs in type 2 diabetes show modest improvements in HbA1c and fasting glucose.
Postmenopausal pain, vasomotor symptoms, and bone metabolism
The 24-month RESHAW trial (Resveratrol Supporting Healthy Aging in Women) — the longest resveratrol study to date — demonstrated that 75 mg twice daily in 125 postmenopausal women produced significant reductions in pain perception, vasomotor symptoms (hot flushes, night sweats), somatic symptoms (joint and muscle discomfort), sleep disturbance, and improved overall quality of life. A 2025 systematic review of 10 RCTs (928 participants) confirmed significant improvements in pain scores and bone resorption marker CTX, though effects on general menopausal symptoms varied across studies. Mechanism is partly via estrogen receptor binding (resveratrol acts as a phytoestrogen) and improved cerebrovascular function.
SIRT1 deacetylase activation
Resveratrol directly binds and allosterically activates SIRT1, promoting deacetylation of PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and p53 (DNA damage response).
AMPK pathway stimulation
Resveratrol inhibits mitochondrial ATP synthase at low concentrations, transiently raising AMP:ATP ratio and activating AMPK — improving glucose uptake, fatty acid oxidation, and mitochondrial function.
Estrogenic activity
Resveratrol is a phytoestrogen that binds estrogen receptors (ERα and ERβ) with preferential affinity for ERβ, producing tissue-selective estrogenic effects relevant to bone, brain, and cardiovascular tissue.
RCT of 150 mg/day resveratrol vs. placebo in 11 obese but healthy men over 30 days.
11 obese men. 30-day intervention.
Resveratrol reduced energy expenditure, improved mitochondrial function, lowered HOMA-IR, reduced triglycerides and inflammation markers. Mimicked metabolic effects of caloric restriction.
Systematic review and meta-analysis of 11 RCTs examining resveratrol in type 2 diabetic patients.
Pooled data from 11 RCTs.
Significant reductions in fasting glucose, HbA1c, insulin resistance, and systolic blood pressure. Effect sizes modest but consistent across studies. Well tolerated.
24-month, randomized, double-blind, placebo-controlled, two-period crossover trial. Resveratrol 75 mg twice daily (150 mg/day) vs. placebo. Conducted at the University of Newcastle Clinical Nutrition Research Centre, Australia.
125 healthy postmenopausal women.
Long-term resveratrol supplementation produced significant improvements in pain perception, vasomotor symptoms (hot flushes, night sweats), somatic complaints (heart discomfort, muscle and joint pain), sleep quality, mood, and overall quality of life. Companion publications from the same trial also reported improvements in cerebrovascular function and cognitive performance in postmenopausal women.